| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparative study elucidating the substantial functional defects of electroporated T cells relative to a mechanical SQZ-based approach
|
Hanson, J.
|
|
|
29 |
S10 |
p. x13
|
artikel
|
| 2 |
AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types
|
Marabelle, A.
|
|
|
29 |
S10 |
p. x38
|
artikel
|
| 3 |
A dual-targeting fusion protein, human PVR-4-1BBL for immunotherapy in AML
|
Park, H.-Y.
|
|
|
29 |
S10 |
p. x32-x33
|
artikel
|
| 4 |
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC
|
Mazzaschi, G.
|
|
|
29 |
S10 |
p. x1
|
artikel
|
| 5 |
Analysis of immune checkpoint- and apoptosis-related lymphocyte markers expression and its association with the prevalence of regulatory lymphocyte populations in the establishment of microinvasive cervical carcinoma
|
Kurmyshkina, O.V.
|
|
|
29 |
S10 |
p. x5-x6
|
artikel
|
| 6 |
A network meta-analysis of the frontline immune-checkpoint inhibitor-based regimens in advanced non-small cell lung cancer
|
Kattan, J.G.
|
|
|
29 |
S10 |
p. x22
|
artikel
|
| 7 |
An investigation into the effects of prior irradiation to the tumour mass on murine TIL expansion
|
Azizi, A.
|
|
|
29 |
S10 |
p. x15
|
artikel
|
| 8 |
A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: Result of a phase Ia clinical trial
|
Shen, L.
|
|
|
29 |
S10 |
p. x22-x23
|
artikel
|
| 9 |
Anti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial
|
Velcheti, V.
|
|
|
29 |
S10 |
p. x29
|
artikel
|
| 10 |
Anti-human CD117 CAR T-cells efficiently eliminate hematopoietic stem and CD117-positive AML cells
|
Myburgh, R.
|
|
|
29 |
S10 |
p. x12
|
artikel
|
| 11 |
Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study
|
Chen, S.
|
|
|
29 |
S10 |
p. x11
|
artikel
|
| 12 |
Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients
|
Hakanen, H.
|
|
|
29 |
S10 |
p. x3
|
artikel
|
| 13 |
Anti-tumor effects of a small molecule C-C chemokine receptor 4 inhibitor in mouse tumor models
|
Li, C.
|
|
|
29 |
S10 |
p. x33
|
artikel
|
| 14 |
A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
|
Deva, S.
|
|
|
29 |
S10 |
p. x24-x25
|
artikel
|
| 15 |
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors
|
Schwarze, J.K.
|
|
|
29 |
S10 |
p. x14
|
artikel
|
| 16 |
A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions
|
Marabelle, A.
|
|
|
29 |
S10 |
p. x38
|
artikel
|
| 17 |
A phase II study of autologous tumor infiltrating lymphocytes (TIL; LN-144/LN-145) in patients with solid tumors
|
Chesney, J.
|
|
|
29 |
S10 |
p. x15-x16
|
artikel
|
| 18 |
A small molecule human PD-1/PD-L1 inhibitor promotes T cell immune activation and reduces tumor growth in a preclinical model
|
Vilalta Colomer, M.
|
|
|
29 |
S10 |
p. x24
|
artikel
|
| 19 |
A SNP germinal signature for predicting checkpoint inhibitor treatment outcome
|
Milano, G.
|
|
|
29 |
S10 |
p. x4
|
artikel
|
| 20 |
A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial)
|
Sunakawa, Y.
|
|
|
29 |
S10 |
p. x9
|
artikel
|
| 21 |
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad hoc expanded access program (EAP)
|
Ascierto, P.A.
|
|
|
29 |
S10 |
p. x29
|
artikel
|
| 22 |
Balancing the efficacy and toxicity of anti-CD47 antibodies by direct screening in humanized mouse models
|
Li, Y.
|
|
|
29 |
S10 |
p. x35
|
artikel
|
| 23 |
Baseline CRP predicts severe immune related adverse events
|
Verheijden, R.
|
|
|
29 |
S10 |
p. x2
|
artikel
|
| 24 |
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
|
Awada, G.
|
|
|
29 |
S10 |
p. x7
|
artikel
|
| 25 |
Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
|
Rolland, S.
|
|
|
29 |
S10 |
p. x31
|
artikel
|
| 26 |
CAR-modified natural killer cell line expressing CD47/SIRPa blockers as a combined approach for solid cancer therapy
|
Chikaev, A.
|
|
|
29 |
S10 |
p. x12
|
artikel
|
| 27 |
Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study
|
He, A.R.
|
|
|
29 |
S10 |
p. x26
|
artikel
|
| 28 |
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
|
Moreno, V.
|
|
|
29 |
S10 |
p. x26
|
artikel
|
| 29 |
Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts
|
Rischin, D.
|
|
|
29 |
S10 |
p. x27-x28
|
artikel
|
| 30 |
CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists
|
Penault-Llorca, F.
|
|
|
29 |
S10 |
p. x9
|
artikel
|
| 31 |
Circulating RNAs in advanced colorectal cancer patients reveal increased expression of PD-1 with conventional CRC therapy
|
Nasrullah, M.
|
|
|
29 |
S10 |
p. x34
|
artikel
|
| 32 |
Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
|
Christopoulos, P.
|
|
|
29 |
S10 |
p. x3-x4
|
artikel
|
| 33 |
Correlative analysis of gene expression changes and PD-L1 immunoexpression in non-small cell lung cancer
|
Guerreiro, I.M.C.
|
|
|
29 |
S10 |
p. x5
|
artikel
|
| 34 |
Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: Implications for the management of irAEs
|
Draghi, A.
|
|
|
29 |
S10 |
p. x18
|
artikel
|
| 35 |
Dissecting the antitumor immune response upon PARP inhibition in homologous recombination repair (HRR)-deficient tumors
|
Pellegrino, B.
|
|
|
29 |
S10 |
p. x6
|
artikel
|
| 36 |
Dissecting the spatial heterogeneity of single CTCs reveals immune evasion through MAX regulated CCL5 overexpression in hepatocellular carcinoma
|
Sun, Y.
|
|
|
29 |
S10 |
p. x1-x2
|
artikel
|
| 37 |
Drug Index
|
|
|
|
29 |
S10 |
p. x44
|
artikel
|
| 38 |
Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
|
Rizvi, N.A.
|
|
|
29 |
S10 |
p. x40-x41
|
artikel
|
| 39 |
Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma
|
Rochigneux, P.
|
|
|
29 |
S10 |
p. x7
|
artikel
|
| 40 |
Editorial board
|
|
|
|
29 |
S10 |
p. ii-iii
|
artikel
|
| 41 |
Effective treatment of nasopharyngeal carcinoma with autologous Epstein-Barr Virus and oncogene–targeted cytotoxic t lymphocytes
|
Xia, W.
|
|
|
29 |
S10 |
p. x15
|
artikel
|
| 42 |
Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials
|
Chalabi, M.
|
|
|
29 |
S10 |
p. x17
|
artikel
|
| 43 |
Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)
|
Grohe, C.
|
|
|
29 |
S10 |
p. x19
|
artikel
|
| 44 |
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
|
Reck, M.
|
|
|
29 |
S10 |
p. x43
|
artikel
|
| 45 |
Efficacy and safety of tabelecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV+ LMS)
|
Kurlander, L.S.
|
|
|
29 |
S10 |
p. x12
|
artikel
|
| 46 |
EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
|
Sriuranpong, V.
|
|
|
29 |
S10 |
p. x37-x38
|
artikel
|
| 47 |
Enhancing NY-ESO-1 antigen expression in lung cancer cells through gene hypomethylation using 5-Aza-2′-deoxycytidine
|
Dermime, S.
|
|
|
29 |
S10 |
p. x36
|
artikel
|
| 48 |
Evaluating safety and efficacy of immune checkpoint inhibitors (ICI) in elderly patients (pts) for advanced cancer treatment: A retrospective study
|
Brixius, S.J.
|
|
|
29 |
S10 |
p. x19
|
artikel
|
| 49 |
Evaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME)
|
Fumet, J.-D.
|
|
|
29 |
S10 |
p. x31
|
artikel
|
| 50 |
Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
|
Gandara, D.R.
|
|
|
29 |
S10 |
p. x39
|
artikel
|
| 51 |
First evidence of antitumor activity of ITPP, a novel hypoxia-modifier: Results of a phase Ib trial
|
Schneider, M.A.
|
|
|
29 |
S10 |
p. x35
|
artikel
|
| 52 |
First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
|
Velcheti, V.
|
|
|
29 |
S10 |
p. x18
|
artikel
|
| 53 |
First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
|
Wang, M.
|
|
|
29 |
S10 |
p. x22
|
artikel
|
| 54 |
Glioblastoma multiforme cells are sensitive to lysis mediated by killer dendritic cells via granule-dependent and death receptor-dependent mechanisms of cytotoxicity
|
Tyrinova, T.
|
|
|
29 |
S10 |
p. x14
|
artikel
|
| 55 |
Harnessing copper in cancer to enhance anti-tumor immune response
|
Voli, F.
|
|
|
29 |
S10 |
p. x35
|
artikel
|
| 56 |
Human PD-1/OX40 double knock-in mouse, a novel model for evaluating in vivo efficacy of the combination therapy of immune-oncology drugs
|
Gan, T.
|
|
|
29 |
S10 |
p. x30
|
artikel
|
| 57 |
Identification of serum microRNAs predicting the response to nivolumab in patients with advanced gastric cancer
|
Miyamoto, T.
|
|
|
29 |
S10 |
p. x3
|
artikel
|
| 58 |
Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme
|
Baldini, E.
|
|
|
29 |
S10 |
p. x18-x19
|
artikel
|
| 59 |
Immunosuppressive mechanisms in acute myeloid leukemia with mutated nucleophosmin
|
Kuželová, K.
|
|
|
29 |
S10 |
p. x32
|
artikel
|
| 60 |
Impact of different GMP media in the production of dendritic cells for next-generation cancer immunotherapy: Functional and metabolic characterization
|
Calmeiro, J.
|
|
|
29 |
S10 |
p. x14
|
artikel
|
| 61 |
IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
|
Califano, R.
|
|
|
29 |
S10 |
p. x17
|
artikel
|
| 62 |
Incidence of programmed cell death 1 inhibitor-related diarrhea in patients with advanced cancer: A systematic review and meta-analysis
|
Sui, J.-D.
|
|
|
29 |
S10 |
p. x19
|
artikel
|
| 63 |
Increased antitumour activity and extravasation of immune checkpoint inhibitor due to hyaluronidase expressed from oncolytic adenovirus VCN-01 and generation of new viruses with improved hyaluronidase activity
|
Farrera, M.
|
|
|
29 |
S10 |
p. x33-x34
|
artikel
|
| 64 |
Inflamed human oropharyngeal cancers with ongoing tumor-specific T cell responses comprise a different type of immune suppressive T cells
|
Santegoets, S.J.
|
|
|
29 |
S10 |
p. x15
|
artikel
|
| 65 |
Interest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy
|
Marton, C.
|
|
|
29 |
S10 |
p. x13
|
artikel
|
| 66 |
Is the current healthcare system ready to treat all eligible patients using car t-cell therapies? An analysis of the NHL situation in France
|
Verrier, T.
|
|
|
29 |
S10 |
p. x23
|
artikel
|
| 67 |
Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T™ cells in advanced solid tumors: Preliminary results from a dose escalation study
|
Becerra, C.R.
|
|
|
29 |
S10 |
p. x24
|
artikel
|
| 68 |
Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
|
Herbst, R.S.
|
|
|
29 |
S10 |
p. x42-x43
|
artikel
|
| 69 |
Lymphotoxin alpha functional germline genetic variant: A future prognostic factor in colorectal cancer?
|
Rocha, M.S.
|
|
|
29 |
S10 |
p. x8
|
artikel
|
| 70 |
Monocyte-to-lymphocye ratio (MLR) and LDH level in metastatic colorectal cancer (mCRC) patients (pts)
|
Basile, D.
|
|
|
29 |
S10 |
p. x3
|
artikel
|
| 71 |
30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial)
|
Rozeman, E.A.
|
|
|
29 |
S10 |
p. x42
|
artikel
|
| 72 |
MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies
|
Galon, J.
|
|
|
29 |
S10 |
p. x4
|
artikel
|
| 73 |
New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer
|
Dorigo, O.
|
|
|
29 |
S10 |
p. x31
|
artikel
|
| 74 |
Nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas
|
Rogacheva, Y.
|
|
|
29 |
S10 |
p. x20-x21
|
artikel
|
| 75 |
Novel CTLA4 antibodies demonstrate potent anti-tumor activity in humanized CTLA4 mouse model
|
Guo, C.
|
|
|
29 |
S10 |
p. x28-x29
|
artikel
|
| 76 |
Oncolysis dominated therapeutic effect of LCMV-GP – pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model
|
Wollmann, G.
|
|
|
29 |
S10 |
p. x37
|
artikel
|
| 77 |
Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody
|
Lakins, M.A.
|
|
|
29 |
S10 |
p. x30
|
artikel
|
| 78 |
Optimizing novel anti-4-1BB antibodies on a in vivo drug screening platform
|
Yang, Y.
|
|
|
29 |
S10 |
p. x30
|
artikel
|
| 79 |
Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways
|
Ren, T.
|
|
|
29 |
S10 |
p. x8
|
artikel
|
| 80 |
PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells
|
Merhi, M.
|
|
|
29 |
S10 |
p. x14-x15
|
artikel
|
| 81 |
PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer
|
Heskamp, S.
|
|
|
29 |
S10 |
p. x7
|
artikel
|
| 82 |
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
|
Babiker, H.M.
|
|
|
29 |
S10 |
p. x27
|
artikel
|
| 83 |
Phase I safety and pharmacokinetics of ADU-1604, an anti-CTLA-4 antibody, in adults with metastatic melanoma
|
Hendriks, M.
|
|
|
29 |
S10 |
p. x37
|
artikel
|
| 84 |
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
|
Owonikoko, T.K.
|
|
|
29 |
S10 |
p. x25
|
artikel
|
| 85 |
PIG-C and SOCS3: Potential immunotargets regulated by non-coding RNAs in TNBC
|
Armanios, M.M.
|
|
|
29 |
S10 |
p. x36
|
artikel
|
| 86 |
Pooling signaling and costimulatory domains in a flexible CARpool design
|
Springuel, L.
|
|
|
29 |
S10 |
p. x12-x13
|
artikel
|
| 87 |
Post-progression evaluation of patients treated with nivolumab for advanced non-small cell lung cancer: A prospective cohort analysis
|
Quaquarini, E.
|
|
|
29 |
S10 |
p. x22
|
artikel
|
| 88 |
Pre-clinical evaluation of bifunctional SIRPα-antibody fusion proteins for the treatment of acute myeloid leukemia
|
Pascual Ponce, L.
|
|
|
29 |
S10 |
p. x32
|
artikel
|
| 89 |
Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)
|
Marabelle, A.
|
|
|
29 |
S10 |
p. x10
|
artikel
|
| 90 |
Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
|
Prelaj, A.
|
|
|
29 |
S10 |
p. x2
|
artikel
|
| 91 |
Preliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers
|
Gudi, G.
|
|
|
29 |
S10 |
p. x34
|
artikel
|
| 92 |
Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies
|
Seitz, L.C.
|
|
|
29 |
S10 |
p. x28
|
artikel
|
| 93 |
Prospective study of circulating tumor cells in long survivors of immunotherapy
|
Brenes Fernández, M.A.
|
|
|
29 |
S10 |
p. x2
|
artikel
|
| 94 |
Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
|
Homicsko, K.
|
|
|
29 |
S10 |
p. x40
|
artikel
|
| 95 |
Relation between IDH1 status, histologic grade, immune-cell infiltration and expression of immune-related genes in patients with gliomas
|
Cabezas-Camarero, S.
|
|
|
29 |
S10 |
p. x5
|
artikel
|
| 96 |
Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
|
Pfarr, N.
|
|
|
29 |
S10 |
p. x8-x9
|
artikel
|
| 97 |
Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials
|
Gogas, H.
|
|
|
29 |
S10 |
p. x21
|
artikel
|
| 98 |
Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast
|
Quiroga, V.
|
|
|
29 |
S10 |
p. x32
|
artikel
|
| 99 |
Safety and clinical outcome in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
|
Halama, N.
|
|
|
29 |
S10 |
p. x30-x31
|
artikel
|
| 100 |
Signs of immunosenescence in patients diagnosed with non-small cell lung cancer
|
Soria Comes, T.
|
|
|
29 |
S10 |
p. x6
|
artikel
|
| 101 |
Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types
|
Kuziora, M.
|
|
|
29 |
S10 |
p. x1
|
artikel
|
| 102 |
SQZing cells to rapidly generate antigen presenting cells (APC) for solid tumor immune therapies with efficient, scalable manufacturing
|
Loughhead, S.M.
|
|
|
29 |
S10 |
p. x13
|
artikel
|
| 103 |
Standardized and compliant bio-informatics pipeline for neoepitope analysis in oncology clinical trials
|
Masloboeva-Siwach, N.
|
|
|
29 |
S10 |
p. x34-x35
|
artikel
|
| 104 |
Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options
|
van der Kooij, M.K.
|
|
|
29 |
S10 |
p. x11
|
artikel
|
| 105 |
Table of Contents
|
|
|
|
29 |
S10 |
p. iv
|
artikel
|
| 106 |
Targeting human CD141+ DC using CLEC9A antibodies for cancer immunotherapy
|
Masterman, K.-A.
|
|
|
29 |
S10 |
p. x35-x36
|
artikel
|
| 107 |
Targeting the tumor stroma with a bispecific T-cell engager-armed oncolytic adenovirus
|
de Sostoa Pomés, J.
|
|
|
29 |
S10 |
p. x34
|
artikel
|
| 108 |
T cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma
|
Pedrazzoli, P.
|
|
|
29 |
S10 |
p. x11
|
artikel
|
| 109 |
The effect of tumor derived HMBG1 on intra-tumoral B cells in esophageal squamous cell carcinoma
|
Kwong, D.L.W.
|
|
|
29 |
S10 |
p. x7-x8
|
artikel
|
| 110 |
The efficacy and safety of rechallenge with an alternative immune checkpoint inhibitor in metastatic malignant melanoma
|
Suwaidan, A.A.
|
|
|
29 |
S10 |
p. x19-x20
|
artikel
|
| 111 |
The impact of HIPEC on the anticancer immune response
|
Roth, L.
|
|
|
29 |
S10 |
p. x36-x37
|
artikel
|
| 112 |
The predictive value of 18F-FDG PET/CT after ipilimumab for treatment response evaluation in metastatic melanoma patients
|
Vari, S.
|
|
|
29 |
S10 |
p. x23
|
artikel
|
| 113 |
The prognostic significance of androgen receptor phosphorylation and the immune infiltrate in prostate cancer
|
Gan, H.W.G.
|
|
|
29 |
S10 |
p. x6
|
artikel
|
| 114 |
The real-world impact of cancer immunotherapy on the survival of patients with metastatic melanoma
|
Donia, M.
|
|
|
29 |
S10 |
p. x21-x22
|
artikel
|
| 115 |
The unexpected challenges of immunotherapy
|
Olsson-Brown, A.C.
|
|
|
29 |
S10 |
p. x20
|
artikel
|
| 116 |
Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
|
Sandhu, S.
|
|
|
29 |
S10 |
p. x28
|
artikel
|
| 117 |
Translational Research Index
|
|
|
|
29 |
S10 |
p. x45-x46
|
artikel
|
| 118 |
Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy
|
Lauret, E.
|
|
|
29 |
S10 |
p. x33
|
artikel
|
| 119 |
Unsupervised analysis of the extent, organization and phenotype of tumor-infiltrating lymphocytes in breast cancer identifies two major clusters
|
Solinas, C.
|
|
|
29 |
S10 |
p. x8
|
artikel
|
| 120 |
Using a multiplexed immunofluorescence assay to detect immunosuppressive cells and their mechanisms in the pancreatic tumor microenvironment
|
Juncker-Jensen, A.
|
|
|
29 |
S10 |
p. x5
|
artikel
|
Tijdschrift beschrijving